Angela DeMichele, MD, MSCE, discusses patient adherence to new oral chemotherapy agents


June 1, 2009

Penn Medicine News Release

Angela DeMichele, MD, MSCE, an associate professor in the division of Hematology/Oncology and the department of Epidemiology, is quoted in a Forbes story addressing the high costs of chemotherapy agents in the face of disappointing study results like those on the drug Avastin which were presented at this weekend's meeting of the American Society of Clinical Oncology. The drug can cost more than $50,000 a year, but may not impact patients' overall survival. DeMichele says that better targeting the patients who will benefit from this and other new agents will be key to trimming the spiraling costs associated with the drugs. There are clues as to how patients mostly likely to benefit from Avastin might be identified, she says, but these avenues haven't been pursued yet. "We're still treating people in an unselected way," DeMichele says... Read More

Forbes Article

ScienceDaily Article
Wall Street Journal (access may be restricted)